BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference
January 06 2021 - 07:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that
the company will present at the 39th Annual J.P. Morgan Healthcare
Conference, which is being conducted as a virtual event, on
Wednesday, January 13, 2021 at 11:40 a.m. ET.
Links to a live audio webcast and replay of the
presentation may be accessed in the Investors section of BioCryst’s
website at http://www.biocryst.com.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. Oral, once-daily
ORLADEYO™ (berotralstat) is approved in the United States for the
prevention of HAE attacks in adults and pediatric patients 12 years
and older, and under regulatory review for approval in Japan and
the European Union. BioCryst has several ongoing development
programs including BCX9930, an oral Factor D inhibitor for the
treatment of complement-mediated diseases, BCX9250, an ALK-2
inhibitor for the treatment of fibrodysplasia ossificans
progressiva, and galidesivir, a potential treatment for Marburg
virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a
viral neuraminidase inhibitor for the treatment of influenza, has
received regulatory approval in the U.S., Canada, Australia, Japan,
Taiwan and Korea. Post-marketing commitments for RAPIVAB are
ongoing. For more information, please visit the Company’s website
at www.biocryst.com.
BCRXW
Investor Contact:John Bluth+1
919 859 7910jbluth@biocryst.com
Media Contact:Catherine Collier
Kyroulis+1 917 886 5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2023 to Mar 2024